BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115

NCT01597622 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Belimumab

Sponsor

GlaxoSmithKline

Collaborators

[object Object]